| Datum | Zeit | Quelle | Überschrift | Symbol | Firma |
| 26/09/2024 | 12h00 | GlobeNewswire Inc. | Centessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024) | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 20/09/2024 | 22h55 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 20/09/2024 | 22h01 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 13/09/2024 | 22h02 | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 13/09/2024 | 22h00 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 13/09/2024 | 04h34 | GlobeNewswire Inc. | Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 13/09/2024 | 02h01 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 11/09/2024 | 22h40 | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 11/09/2024 | 22h04 | GlobeNewswire Inc. | Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 11/09/2024 | 22h01 | Edgar (US Regulatory) | Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 10/09/2024 | 22h06 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 10/09/2024 | 13h08 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 10/09/2024 | 13h00 | GlobeNewswire Inc. | Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 27/08/2024 | 14h00 | GlobeNewswire Inc. | Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024) | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 23/08/2024 | 23h13 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 23/08/2024 | 22h13 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 22/08/2024 | 23h15 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 22/08/2024 | 22h13 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 21/08/2024 | 22h38 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 21/08/2024 | 14h00 | GlobeNewswire Inc. | Centessa Pharmaceuticals to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 20/08/2024 | 22h52 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 13/08/2024 | 13h27 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 13/08/2024 | 13h15 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 13/08/2024 | 13h00 | GlobeNewswire Inc. | Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024 | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 10/06/2024 | 13h13 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 10/06/2024 | 13h00 | GlobeNewswire Inc. | Centessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as Chief Financial Officer and Gregory Weinhoff MD MBA, as Chief Business Officer | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 21/05/2024 | 14h45 | GlobeNewswire Inc. | Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 13/05/2024 | 22h32 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 13/05/2024 | 22h23 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 13/05/2024 | 22h10 | GlobeNewswire Inc. | Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024 | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |